Twist Bioscience announced the expansion of its growing portfolio of synthetic viral controls with the launch of a synthetic RNA control for H5N1 Influenza A, which is one of the causes of Highly Pathogenic Avian Influenza HPAI or bird flu, covering 99.9% of hemagglutinin HA and neuraminidase NA genome regions. “As agricultural and infectious disease researchers around the world continue to monitor the spread of H5N1, we continue our unwavering commitment to responding rapidly to threats to public health by providing innovative and critical tools to safeguard our global community and enable monitoring and surveillance as well as vaccine and assay development,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. ”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $60 from $45 at Barclays
- Twist Bioscience price target raised to $65 from $55 at TD Cowen
- Twist publishes study detailing the discovery of TB206-001 targeting A2AR
- Twist extends rally as Wall Street sees opportunity amid GenScript scrutiny
- Twist Bioscience initiated with a Buy at Guggenheim (yesterday)